TY - JOUR
T1 - Allogeneic mesenchymal precursor cells (MPCs)
T2 - an innovative approach to treating advanced heart failure
AU - Westerdahl, Daniel E.
AU - Chang, David H.
AU - Hamilton, Michele A.
AU - Nakamura, Mamoo
AU - Henry, Timothy D.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Introduction: Over 37 million people worldwide are living with Heart Failure (HF). Advancements in medical therapy have improved mortality primarily by slowing the progression of left ventricular dysfunction and debilitating symptoms. Ultimately, heart transplantation, durable mechanical circulatory support (MCS), or palliative care are the only options for patients with end-stage HF. Regenerative therapies offer an innovative approach, focused on reversing myocardial dysfunction and restoring healthy myocardial tissue. Initial clinical trials using autologous (self-donated) bone marrow mononuclear cells (BMMCs) demonstrated excellent safety, but only modest efficacy. Challenges with autologous stem cells include reduced quality and efficacy with increased patient age. The use of allogeneic mesenchymal precursor cells (MPCs) offers an “off the shelf” therapy, with consistent potency and less variability than autologous cells. Areas covered: Preclinical and initial clinical trials with allogeneic MPCs have been encouraging, providing the support for a large ongoing Phase III trial—DREAM-HF. We provide a comprehensive review of preclinical and clinical data supporting MPCs as a therapeutic option for HF patients. Expert opinion: The current data suggest allogeneic MPCs are a promising therapy for HF patients. The results of DREAM-HF will determine whether allogeneic MPCs can decrease major adverse clinical events (MACE) in advanced HF patients.
AB - Introduction: Over 37 million people worldwide are living with Heart Failure (HF). Advancements in medical therapy have improved mortality primarily by slowing the progression of left ventricular dysfunction and debilitating symptoms. Ultimately, heart transplantation, durable mechanical circulatory support (MCS), or palliative care are the only options for patients with end-stage HF. Regenerative therapies offer an innovative approach, focused on reversing myocardial dysfunction and restoring healthy myocardial tissue. Initial clinical trials using autologous (self-donated) bone marrow mononuclear cells (BMMCs) demonstrated excellent safety, but only modest efficacy. Challenges with autologous stem cells include reduced quality and efficacy with increased patient age. The use of allogeneic mesenchymal precursor cells (MPCs) offers an “off the shelf” therapy, with consistent potency and less variability than autologous cells. Areas covered: Preclinical and initial clinical trials with allogeneic MPCs have been encouraging, providing the support for a large ongoing Phase III trial—DREAM-HF. We provide a comprehensive review of preclinical and clinical data supporting MPCs as a therapeutic option for HF patients. Expert opinion: The current data suggest allogeneic MPCs are a promising therapy for HF patients. The results of DREAM-HF will determine whether allogeneic MPCs can decrease major adverse clinical events (MACE) in advanced HF patients.
KW - Heart failure
KW - intramyocardial injection
KW - mesenchymal precursor cell
KW - mesenchymal progenitor cell
KW - myocardial regeneration
KW - stem cells
KW - therapeutic biologics
KW - tissue therapy
UR - http://www.scopus.com/inward/record.url?scp=84978119371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978119371&partnerID=8YFLogxK
U2 - 10.1080/14712598.2016.1206526
DO - 10.1080/14712598.2016.1206526
M3 - Article
C2 - 27376188
AN - SCOPUS:84978119371
SN - 1471-2598
VL - 16
SP - 1163
EP - 1169
JO - Expert opinion on biological therapy
JF - Expert opinion on biological therapy
IS - 9
ER -